UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of August 2024
Commission
File Number: 001-32371
SINOVAC BIOTECH LTD.
No. 39
Shangdi Xi Rd, Haidian District
Beijing 100085, People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F ¨
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
SINOVAC BIOTECH LTD. |
| |
|
|
| |
By: |
/s/ Nan Wang |
| |
Name: |
Nan Wang |
| |
Title: |
Chief Financial Officer |
Date: August 16,
2024
Exhibit Index
Exhibit 99.1 Press Release
Exhibit 99.1
SINOVAC
Reports Unaudited First Half of 2024 Financial Results
BEIJING,
China, August 16, 2024 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC”
or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results
for the six months ended June 30, 2024.
First
Half of 2024 Financial Summary
| · | Sales for the six months
ended June 30, 2024 were $121.3 million, compared to $140.4 million in the prior year period. |
| · | The Company posted $10.9
million of net loss attributable to common shareholders, or a loss of $0.11 per basic and diluted share, in the six-month period ended
June 30, 2024, compared to net income attributable to common shareholders of $14.0 million, or $0.14 per basic and $0.15 per diluted
share, in the prior year period. |
| · | Mr. Weidong Yin, Chairman, President and
CEO of SINOVAC, commented, “In the first half of the year, SINOVAC focused on executing its regular vaccine business strategies.
Although the COVID-19 pandemic is over, there are still challenges from various infectious diseases. SINOVAC provided vaccines in time
during the epidemic of hepatitis A and influenza in Brazil, Chile and other countries to minimize the shortage of vaccine supplies, continuing
our vital role similar to it in the COVID-19 pandemic period. Furthermore, it is great to see other progress in the international market
where SINOVAC’s local joint venture won long-term public tenders in Türkiye.” |
Business Updates
| · | Hepatitis A Vaccine – Healive®,
the first and only WHO prequalified inactivated hepatitis A vaccine from China, is currently supplied both domestically and internationally.
Healive®’s performance in international market substantially grew in the first half of 2024. |
| · | Influenza Vaccine – SINOVAC has
two influenza vaccine production plants. The plants, which comply with Chinese Good Manufacturing Practice (or “GMP”) guidelines
and utilize environmental-friendly production process, enable automated production at commercial scale so that SINOVAC has more capacity
to meet the growing global demand for high-quality influenza vaccines. SINOVAC’s influenza vaccines kept expanding its international
market presence in 2024 by obtaining more overseas market approvals, won public tenders in Pakistan and were supplied to Chile for the
flu emergency. A study conducted last year in the Philippines and Chile demonstrated that the immunogenicity induced by SINOVAC’s
quadrivalent influenza vaccine was non-inferior and the geometric mean titers (or “GMT”) were even higher in individuals aged
3 years and older, when compared with the control vaccine which was widely used. The research result was published in Vaccines in 2024.
Furthermore, SINOVAC completed phase III clinical trials of quadrivalent influenza in infants and toddlers aged 6-35 months in the first
half of 2024. |
| · | Varicella Vaccine – SINOVAC’s
live attenuated varicella vaccine, the first WHO prequalified (or “PQ”) Chinese varicella vaccine, was successfully supplied
to more countries this year. SINOVAC's varicella vaccine, which had been previously approved for children aged 12 months to 12 years old,
was approved by China NMPA for use in adolescents and adults aged 13 years old and above in June 2024. SINOVAC’s varicella
vaccine obtained its first international GMP certificate in the Philippines in January 2024. |
| · | Hand Foot and Mouth Disease Vaccine –
SINOVAC’s Enterovirus 71 (or “EV71”) Vaccine, Inlive®, has already safeguarded millions of children
in China. In 2023, SINOVAC initiated phase I and II clinical trials of its bivalent enterovirus inactivated vaccine, which aims to protect
against hand, foot and mouth disease (or “HFMD”) caused by EV71 and coxsackievirus 16 (or “CA16”). CA16 is the
dominant strain and is widespread in China and other Asian regions. At present, the enrollment of all the participants of this study has
been completed. Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®’ project participated by SINOVAC
won second prize of the PRC National Science and Technology Progress Award 2023. In 2024, SINOVAC's EV71 vaccine was approved for use
in Macao, China. |
| · | Poliomyelitis Vaccine (Vero Cell), Inactivated,
Sabin Strains – SINOVAC's Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains (0.5ml/vial) (or "sIPV")
received WHO PQ on June 2, 2022. Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains (Five-Dose) (2.5ml/vial) (or
"msIPV") was authorized in April 2024 by the China NMPA for market use. Since msIPV is mainly for UNICEF and PAHO procurement,
SINOVAC is currently applying msIPV for WHO PQ approval so supply msIPV to the above international organizations can be achieved at the
earliest date. |
| · | Reassortant Rotavirus Vaccine –
SINOVAC has initiated phase I clinical trials of its Reassortant Rotavirus Vaccine, Live, Oral, Hexavalent (Vero Cell). The vaccine covers
six rotavirus serotypes, G1, G2, G3, G4, G9, and P1A. It is one of the rotavirus vaccines with a broad-spectrum protection currently marketed
or under development in the world. By the first half of 2024, this phase I clinical trial has finished enrollment and vaccination of adults
and children participants, and enrollment of infants participants is ongoing and expected to be finished in the third quarter of 2024. |
| · | Adsorbed Tetanus Vaccine – The results
of phase I/III clinical study of the adsorbed tetanus vaccine developed by SINOVAC were favorable. The antibody conversion rate of volunteers
in the phase III clinical trial reached 99.48% in 30 days after vaccination, which reached the non-inferiority standard; the geometric
mean concentration (or “GMC”) of antibodies reached statistical superiority. |
| · | Commercial Developments – SINOVAC
made significant progress in commercial development in the first half of 2024. In Türkiye, the first overseas joint venture company
invested by SINOVAC won two long-term public tenders for the hepatitis A vaccine and varicella vaccine. SINOVAC's extensive expertise
and experience in vaccine R&D and production, as well as its successful track record in establishing vaccine facilities, will play
a pivotal role in the joint venture. |
Unaudited
Financial Results for the First Half of 2024
Sales
for the first half of 2024 were $121.3 million compared to $140.4 million in the prior year period. Although Healive®’s
sales for the first half of 2024 increased due to international market growth, however, as newborn
rates in China continue to decline, sales of EV71 vaccines, which are primarily used in young children, have been impacted, resulting
in a decrease in the Company’s revenue in the first half of 2024.
Selling,
general and administrative expenses in the first half of 2024 were $206.3 million, compared to $231.0 million in the prior year period.
The decrease was mainly due to lower employee incentive expenses associated with a COVID-19 employee incentive plan established in 2022.
R&D
expenses in the first half of 2024 were $144.1 million, compared to $151.1 million in the prior year period.
Net loss
in the first half of 2024 was $68.6 million, compared to a net loss of $30.0 million in the prior year period.
Net loss
attributable to common shareholders was $10.9 million, or a loss of $0.11 per basic and diluted share, in the first half of 2024, compared
to a net income attributable to common shareholders of $14.0 million, or $0.14 per basic and $0.15 per diluted share, in the prior year
period.
As the Company
announced on February 22, 2019, the Company’s board of directors determined that certain shareholders became acquiring persons,
as defined in the Company’s rights agreement (“Rights Agreement”), under which a trigger event occurred. As a result,
the Company issued new common and preferred shares of SINOVAC. Without the effect of implementing the Rights Agreement and newly-issued
common and preferred shares, basic and diluted loss per share for the first half of 2024 would be $0.11.
Non-GAAP
adjusted EBITDA was $204.2 million loss in the first half of 2024, compared to $346.6 million loss in the prior year period. Non-GAAP
net loss was $82.3 million in the first half of 2024, compared to $120.9 million net loss in the prior year period. Non-GAAP diluted loss
per share in the first half of 2024 was $0.16 compared to a loss of $0.32 per share in the prior year period. Non-GAAP diluted loss per
share in the first half of 2024, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares,
would be $0.22. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this news release.
As of June 30,
2024, cash and cash equivalents and restricted cash totaled $1.1 billion, compared to $1.3 billion as of December 31, 2023. In the
first half of 2024, net cash used in operating activities was $438.9 million, net cash provided by investing activities was $436.8 million
reflecting the net position of short-term investment redemptions over purchases, and net cash used in financing activities was $171.2
million.
The Company’s
first half of 2024 financial statements are prepared and presented in accordance with U.S. GAAP. However, they have not been audited or
reviewed by the Company’s independent registered accounting firm.
Legal
Proceedings
As previously disclosed
by the Company, on March 13, 2018, 1Globe Capital LLC (“1Globe”) filed a complaint against the Company in the Antigua
Court. The trial of the matter took place from December 3 to 5, 2018. On December 19, 2018, the Antigua judge handed down his
judgment (the “Antigua Judgment”), finding the Company fully in favor, dismissing 1Globe’s claim and declaring the Rights
Agreement was validly adopted as a matter of Antigua law. On January 29, 2019, 1Globe filed a Notice of Appeal against the Antigua
Judgment. On March 4, 2019, 1Globe filed an application for urgent interim relief, seeking an injunction to prevent the Company from
continuing to implement its Rights Agreement until the resolution of the appeal. This application was heard on April 4, 2019, at
which the Court of Appeal issued an order restraining the Company from operating the Rights Agreement in any way that affects 1Globe’s
rights or shareholding or otherwise distributing the exchange shares (the “Exchange Shares”) to the Company’s shareholders
who did not trigger the Rights Plan until after the determination of the appeal (the “Exchange Shares”). 1Globe’s appeal
against the Antigua Judgment was heard on September 18, 2019, and the appeal decision was announced by the Eastern Caribbean
Supreme Court, Court of Appeal (the “Court of Appeal”) on December 9, 2021, upholding the Antigua Judgment in each point.
1Globe applied for leave to appeal to the Judicial Committee of the Privy Council (the “Privy Council”), and the hearing of
the application was held on February 24, 2022, in which the Court of Appeal granted 1Globe leave to appeal to the Privy Council on
certain grounds, although not including the challenge to the validity of the Rights Agreement. On April 19, 2022, 1Globe renewed
its application directly to the Privy Council for leave to appeal on its ground of appeal concerning the validity of the Rights Agreement.
The final substantive hearing before the Privy Council took place on July 10 to 11, 2024. The Privy Council refused 1Globe permission
to appeal on certain arguments in relation to the validity of the Rights Agreement, and reserved its judgment for other arguments on that
ground of appeal, and in relation to whether to grant 1Globe relief in relation to the outcome of the AGM vote. The judgment will be delivered
in writing at a later date. The appeal outcome is therefore pending.
As previously
disclosed, on March 5, 2018, the Company filed a lawsuit in the Court of Chancery of the State of Delaware, seeking a determination
on whether 1Globe, the Chiang Li Family, OrbiMed Advisors, LLC and certain other shareholders of the Company had triggered the Rights
Agreement. On April 12, 2018, 1Globe filed an amended answer to the Company’s complaint, counterclaims and a third-party complaint
against the Company and Mr. Weidong Yin, alleging, among other allegations, that the Rights Agreement is not valid. On March 6,
2019, the Delaware Chancery Court entered a status quo order, providing that the Company not distribute any of the Exchange Shares to
the Company’s shareholders who did not trigger the Rights Plan until the final disposition of the pending Delaware litigation or
further order of the Court. On April 8, 2019, the Delaware Chancery Court stayed the Delaware litigation pending the final outcome
of 1Globe’s appeal of the Antigua Judgment.
Separately,
Heng Ren Investments LP (“Heng Ren”) filed suits against SINOVAC and Weidong Yin on May 31, 2019 in Massachusetts state
court for the alleged breach of fiduciary duties and wrongful equity dilution. SINOVAC moved the matter from the state court to the United
States District Court for the District of Massachusetts. Heng Ren alleged that Mr. Yin breached fiduciary duties owed to minority
shareholders, that SINOVAC aided and abetted breaches of fiduciary duties and that both SINOVAC and Mr. Yin engaged in wrongful equity
dilution. Heng Ren requested damages, attorney fees, and prejudgment interest. In July 2021, SINOVAC moved to dismiss Heng Ren’s
amended complaint in the federal court in Massachusetts. On March 4, 2022, the court granted the motion as to the breach of fiduciary
duty claims and denied the motion as to the wrongful equity dilution claim and denied reconsideration of its decision on the motion. On
June 13, 2024, the parties stipulated to a discontinuance of the action with prejudice. SINOVAC did not incur any material expense
in connection with the action.
On September 6,
2023, MW Gestion, an institutional asset manager based in France, filed a class action complaint on behalf of all SINOVAC shareholders
against SINOVAC; Weidong Yin; and other managers and directors of SINOVAC, including Nan Wang, Simon Anderson, Yuk Lam Lo, Kenneth Lee,
Meng Mei, and Shan Fu (the “Individual Defendants” and collectively with SINOVAC the “SINOVAC Defendants”); and
Wilmington Trust National Association. MW Gestion alleges breach of contract, breach of fiduciary duty, and wrongful dilution claims against
the SINOVAC Defendants, as well as aiding and abetting breach of contract and breach of fiduciary duty against the Individual Defendants.
MW Gestion’s claims stem from a private investment in public equity transaction on July 2, 2018, and SINOVAC’s implementation
of its Rights Agreement on February 22, 2019. SINOVAC and certain other defendants filed a motion to dismiss all claims on November 20,
2023, and the motion was fully briefed as of February 27, 2024. A hearing on the motion to dismiss has been scheduled for September 4,
2024.
Status
of Exchange Shares and Trading in the Company’s Shares
As a result
of the pending legal proceedings described above, the Exchange Shares are expected to remain in a trust for the benefit of the Company’s
shareholders who did not trigger the Rights Plan until, at least, the conclusion of the appeal against the Antigua Judgment and the final
disposition of the Delaware litigation or further order of the Delaware Chancery Court. The Exchange Shares remain issued and outstanding.
The Nasdaq Stock Market LLC implemented a halt on trading of the Company’s common shares at the time the Exchange Shares were issued
to the trust. The Company is currently unable to estimate when trading will resume, or if Nasdaq will take any additional action in regard
to trading of the Company’s common shares.
About
SINOVAC
Sinovac
Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of
vaccines that protect against human infectious diseases.
SINOVAC’s
product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella,
influenza, poliomyelitis, pneumococcal disease, mumps, etc.
The COVID-19
vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine,
Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative
vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain
inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC
was the first company to be granted approval for its H1N1 influenza vaccine, Panflu.1®,
which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the
H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC
continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global
market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business
and industry organizations.
For more information,
please visit the Company’s website at www.sinovac.com.
Safe
Harbor Statement
This press release may include certain statements
that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the “safe harbor”
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology
such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,”
“believes,” “estimates” and similar statements. Forward-looking statements involve risks, uncertainties and other
factors that could cause actual results to differ materially from those contained in any such statements. In particular, the outcome of
any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or filed against it by others.
Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company
or its stock price as a result of the trigger of the rights plan.
Non-GAAP
Financial Measures
To supplement
its consolidated financial statements, which are prepared and presented in accordance with GAAP, SINOVAC uses the following non-GAAP financial
measures: non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share. For more information on
these non-GAAP financial measures, please refer to the table captioned “Reconciliations of non-GAAP Measures to the Nearest Comparable
GAAP Measures” in this results announcement.
SINOVAC
believes that non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share help identify underlying
trends in its business that could otherwise be distorted by the effect of certain income or expenses that SINOVAC includes in net income
and diluted earnings (loss) per share. SINOVAC believes that non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted
earnings (loss) per share provide useful information about its core operating results, enhance the overall understanding of its past performance
and future prospects and allow for greater visibility with respect to key metrics used by our management in its financial and operational
decision-making. Non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted
earnings (loss) per share should not be considered in isolation or construed as an alternative to income from operations, net income (loss),
diluted earnings (loss) per share, or any other measure of performance or as an indicator of SINOVAC’s operating performance. These
non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies
may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data.
Non-GAAP
adjusted EBITDA represents net income (loss) and excludes interest and financing expenses,
interest income, net other income (expenses) and income tax benefit (expenses), and certain non-cash expenses, consisting of share-based
compensation expenses, amortization and depreciation that SINOVAC does not believe are reflective
of the core operating performance during the periods presented.
Non-GAAP
net income (loss) represents net income (loss) before
share-based compensation expenses and foreign exchange gain or loss.
Non-GAAP
diluted earnings (loss) per share represents non-GAAP net income (loss) attributable
to common shareholders divided by the weighted average number of shares outstanding during the periods on a diluted basis, including accounting
for the effect of the assumed conversion of options.
Contact
Sinovac
Biotech Ltd.
Helen Yang
Tel: +86-10-8279
9720
Email: ir@sinovac.com
SINOVAC BIOTECH LTD.
Consolidated Balance Sheets
As of June 30, 2024 and December 31, 2023
(Expressed in thousands of U.S. Dollars)
| | |
June 30,
2024 | |
December 31,
2023 | |
| Current assets | |
| | |
| | |
| Cash and cash equivalents | |
$ | 1,072,350 | |
$ | 1,270,131 | |
| Restricted cash | |
| 2,779 | |
| 5,166 | |
| Short-term investments | |
| 9,502,185 | |
| 9,953,042 | |
| Accounts receivable - net | |
| 370,168 | |
| 440,019 | |
| Inventories | |
| 153,524 | |
| 139,874 | |
| Prepaid expenses and deposits | |
| 12,724 | |
| 11,621 | |
| Amounts due from related parties | |
| 23,847 | |
| — | |
| Income tax receivable | |
| 10,703 | |
| 10,703 | |
| Total current assets | |
| 11,148,280 | |
| 11,830,556 | |
| | |
| | |
| | |
| Property, plant and equipment
– net | |
| 934,614 | |
| 979,617 | |
| Prepaid land lease payments | |
| 62,916 | |
| 65,540 | |
| Intangible assets - net | |
| 7,844 | |
| 8,520 | |
| Long-term prepaid expenses | |
| 24 | |
| 24 | |
| Long-term investments | |
| 681,345 | |
| 684,285 | |
| Prepayments for acquisition of
equipment | |
| 4,338 | |
| 6,772 | |
| Deferred tax assets | |
| 32,798 | |
| 29,790 | |
| Right-of-use assets | |
| 15,346 | |
| 45,525 | |
| Other non-current assets | |
| 9,432 | |
| 7,345 | |
| Total assets | |
| 12,896,937 | |
| 13,657,974 | |
| | |
| | |
| | |
| Current liabilities | |
| | |
| | |
| Short-term bank loans and current
portion of long-term bank loans | |
| 179,349 | |
| 76,089 | |
| Accounts payable and accrued
liabilities | |
| 641,579 | |
| 973,949 | |
| Income tax payable | |
| 28,720 | |
| 41,258 | |
| Deferred revenue | |
| 6,173 | |
| 20,127 | |
| Deferred government grants | |
| 805 | |
| 1,586 | |
| Dividend payable | |
| 119,374 | |
| 29,089 | |
| Lease liability | |
| 2,451 | |
| 5,806 | |
| Total current liabilities | |
| 978,451 | |
| 1,147,904 | |
| | |
| | |
| | |
| Deferred government grants | |
| 5,984 | |
| 5,865 | |
| Long-term bank loans | |
| 130,320 | |
| 177,817 | |
| Deferred tax liability | |
| 262,174 | |
| 263,711 | |
| Lease liability | |
| 12,388 | |
| 39,271 | |
| Other non-current liabilities | |
| 429 | |
| 439 | |
| Deferred revenue | |
| 195 | |
| 200 | |
| Total long-term liabilities | |
| 411,490 | |
| 487,303 | |
| | |
| | |
| | |
| Total liabilities | |
| 1,389,941 | |
| 1,635,207 | |
| | |
| | |
| | |
| Commitments and contingencies | |
| | |
| | |
| | |
| | |
| | |
| Equity | |
| | |
| | |
| Preferred stock | |
| 15 | |
| 15 | |
| Common stock | |
| 100 | |
| 100 | |
| Additional paid-in capital | |
| 541,258 | |
| 541,258 | |
| Accumulated other comprehensive
loss | |
| (539,415 | ) |
| (490,055 | ) |
| Statutory surplus reserves | |
| 1,539,584 | |
| 1,539,584 | |
| Accumulated earnings | |
| 7,107,644 | |
| 7,118,516 | |
| Total shareholders' equity | |
| 8,649,186 | |
| 8,709,418 | |
| | |
| | |
| | |
| Non-controlling interests | |
| 2,857,810 | |
| 3,313,349 | |
| Total equity | |
| 11,506,996 | |
| 12,022,767 | |
| Total liabilities and equity | |
$ | 12,896,937 | |
$ | 13,657,974 | |
SINOVAC BIOTECH LTD.
Consolidated Statements of Comprehensive Income (Loss)
For
the six months ended June 30, 2024 and 2023
(Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data)
| | |
Six months ended June 30 | |
| | |
2024 | | |
2023 | |
| Sales | |
$ | 121,339 | | |
$ | 140,404 | |
| Cost of sales | |
| 40,836 | | |
| 188,409 | |
| Gross profit (loss) | |
| 80,503 | | |
| (48,005 | ) |
| | |
| | | |
| | |
| Selling, general and administrative expenses | |
| 206,347 | | |
| 231,048 | |
| Provision for (recovery of) doubtful accounts | |
| (663 | ) | |
| 386 | |
| Research and development expenses | |
| 144,052 | | |
| 151,132 | |
| Loss on disposal of property, plant and equipment | |
| 5,387 | | |
| 312 | |
| Government grants recognized in income | |
| (1,044 | ) | |
| (92 | ) |
| Total operating expenses | |
| 354,079 | | |
| 382,786 | |
| Operating income (loss) | |
| (273,576 | ) | |
| (430,791 | ) |
| | |
| | | |
| | |
| Interest and financing expenses | |
| (2,175 | ) | |
| (264 | ) |
| Interest income | |
| 44,060 | | |
| 29,589 | |
| Other income, net | |
| 166,481 | | |
| 337,856 | |
| Loss before income taxes | |
| (65,210 | ) | |
| (63,610 | ) |
| Income tax benefit (expense) | |
| (3,432 | ) | |
| 33,597 | |
| Net loss | |
| (68,642 | ) | |
| (30,013 | ) |
| Less: loss attributable to non-controlling interests | |
| 60,745 | | |
| 46,931 | |
| Net income (loss) attributable to shareholders of Sinovac | |
| (7,897 | ) | |
| 16,918 | |
| Preferred stock dividends | |
| (2,975 | ) | |
| (2,958 | ) |
| Net income (loss) attributable to common shareholders of Sinovac | |
| (10,872 | ) | |
| 13,960 | |
| | |
| | | |
| | |
| Net loss | |
| (68,642 | ) | |
| (30,013 | ) |
| Other comprehensive income, net of tax of nil | |
| | | |
| | |
| Foreign currency translation adjustments | |
| (194,758 | ) | |
| (448,477 | ) |
| Unrealized gain | |
| 69,612 | | |
| 6,917 | |
| Comprehensive loss | |
| (193,788 | ) | |
| (471,573 | ) |
| Less: comprehensive loss attributable to non-controlling interests | |
| 136,531 | | |
| 217,305 | |
| Comprehensive loss attributable to shareholders of Sinovac | |
| (57,257 | ) | |
| (254,268 | ) |
| | |
| | | |
| | |
| Earnings per share | |
| | | |
| | |
| Basic net income per share | |
| (0.11 | ) | |
| 0.14 | |
| Diluted net income per share | |
| (0.11 | ) | |
| 0.15 | |
| | |
| | | |
| | |
| Weighted average number of shares of common stock outstanding | |
| | | |
| | |
| Basic | |
| 99,638,043 | | |
| 99,576,600 | |
| Diluted | |
| 99,638,043 | | |
| 114,227,276 | |
SINOVAC BIOTECH LTD.
Consolidated Statements of Cash Flows
For
the six months ended June 30, 2024 and 2023
(Expressed in thousands of U.S. Dollars)
| | |
Six
months ended June 30 | |
| | |
2024 | | |
2023 | |
| Operating activities | |
| | | |
| | |
| Net loss | |
$ | (68,642 | ) | |
$ | (30,013 | ) |
| Adjustments to reconcile net
income to net cash provided by operating activities: | |
| | | |
| | |
| Deferred income taxes | |
| (3,718 | ) | |
| (32,124 | ) |
| Inventory provision | |
| 8,340 | | |
| 12,624 | |
| Provision for (recovery of) doubtful
accounts | |
| (663 | ) | |
| 386 | |
| Loss on disposal of property,
plant and equipment | |
| 5,387 | | |
| 312 | |
| Depreciation of property, plant
and equipment | |
| 67,747 | | |
| 82,484 | |
| Amortization of prepaid land
lease payments | |
| 1,093 | | |
| 1,138 | |
| Amortization of intangible assets | |
| 501 | | |
| 527 | |
| Government grants recognized
in income | |
| (1,044 | ) | |
| (92 | ) |
| Loss from equity method investments | |
| 7,640 | | |
| 374 | |
| Investment income | |
| (135,971 | ) | |
| (75,612 | ) |
| | |
| | | |
| | |
| Changes in: | |
| | | |
| | |
| Accounts receivable | |
| 62,928 | | |
| 90,434 | |
| Amounts due from related
parties | |
| (23,847 | ) | |
| — | |
| Inventories | |
| (25,311 | ) | |
| (23,296 | ) |
| Other non-current assets | |
| (2,273 | ) | |
| 2,785 | |
| Income tax payable | |
| (11,676 | ) | |
| (5,824 | ) |
| Prepaid expenses and deposits | |
| (3,272 | ) | |
| 1,583 | |
| Deferred revenue | |
| (13,595 | ) | |
| (2,074 | ) |
| Accounts payables and accrued
liabilities | |
| (302,521 | ) | |
| (47,208 | ) |
| Deferred governments | |
| — | | |
| (16,813 | ) |
| Other non-current liabilities | |
| — | | |
| 418 | |
| | |
| | | |
| | |
| Net cash used in operating
activities | |
| (438,897 | ) | |
| (39,991 | ) |
| | |
| | | |
| | |
| Financing activities | |
| | | |
| | |
| Proceeds from bank loans | |
| 136,207 | | |
| 209,587 | |
| Repayments of bank loans | |
| (74,153 | ) | |
| (150 | ) |
| Proceeds from issuance of common
stock, net of share issuance costs | |
| — | | |
| 676 | |
| Dividend paid to non-controlling
shareholders | |
| (233,375 | ) | |
| (1,616 | ) |
| Government grants received | |
| 141 | | |
| 8,668 | |
| Repayments of loan from a non-controlling
shareholder | |
| — | | |
| (1 | ) |
| | |
| | | |
| | |
| Net cash provided by (used
in) financing activities | |
| (171,180 | ) | |
| 217,164 | |
| | |
| | | |
| | |
| Investing activities | |
| | | |
| | |
| Purchase of short-term investments | |
| (3,427,917 | ) | |
| (6,628,110 | ) |
| Proceeds from redemption of short-term
investments | |
| 3,925,995 | | |
| 4,013,372 | |
| Proceeds from disposal of equipment | |
| 107 | | |
| 37 | |
| Acquisition of property, plant
and equipment | |
| (57,115 | ) | |
| (92,942 | ) |
| Acquisition of intangible assets | |
| (18 | ) | |
| — | |
| Purchase of long-term investments | |
| (4,224 | ) | |
| (24,792 | ) |
| Distributions of equity method
investees | |
| — | | |
| 1,342 | |
| Proceeds from sale or maturity
of long-term investments | |
| — | | |
| 146 | |
| | |
| | | |
| | |
| Net cash provided by (used
in) investing activities | |
| 436,828 | | |
| (2,730,947 | ) |
| | |
| | | |
| | |
| Effect of exchange rate
changes on cash and cash equivalents and restricted cash | |
| (26,919 | ) | |
| (85,843 | ) |
| | |
| | | |
| | |
| Decrease in cash and cash
equivalents and restricted cash | |
| (200,168 | ) | |
| (2,639,617 | ) |
| | |
| | | |
| | |
| Cash and cash equivalents
and restricted cash, beginning of period | |
| 1,275,297 | | |
| 4,286,377 | |
| | |
| | | |
| | |
| Cash and cash equivalents
and restricted cash, end of period | |
| 1,075,129 | | |
| 1,646,760 | |
SINOVAC BIOTECH LTD.
Reconciliations of Non-GAAP measures to the nearest comparable GAAP measures
For
the six months ended June 30, 2024 and 2023
(Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data)
| | |
Six months ended June 30 | |
| | |
2024 | | |
2023 | |
| | |
(Unaudited) | | |
(Unaudited) | |
| Net loss | |
$ | (68,642 | ) | |
$ | (30,013 | ) |
| Adjustments: | |
| | | |
| | |
| Depreciation and amortization | |
| 69,341 | | |
| 84,149 | |
| Interest income, net of interest and financing expenses | |
| (41,885 | ) | |
| (29,325 | ) |
| Other income, net | |
| (166,481 | ) | |
| (337,856 | ) |
| Income tax expense (benefit) | |
| 3,432 | | |
| (33,597 | ) |
| Non-GAAP adjusted EBITDA | |
| (204,235 | ) | |
| (346,642 | ) |
| | |
| | | |
| | |
| Net loss | |
| (68,642 | ) | |
| (30,013 | ) |
| Add: Foreign exchange gain | |
| (13,695 | ) | |
| (90,851 | ) |
| Non-GAAP net loss | |
| (82,337 | ) | |
| (120,864 | ) |
| | |
| | | |
| | |
| Net income (loss) attributable to common shareholders of Sinovac | |
| (10,872 | ) | |
| 13,960 | |
| Add: Preferred stock dividends | |
| 2,975 | | |
| 2,958 | |
| Net income (loss) attributable to common shareholders of Sinovac for computing diluted earnings per share | |
| (7,897 | ) | |
| 16,918 | |
| Add: Non-GAAP adjustments to net income | |
| (8,191 | ) | |
| (53,349 | ) |
| Non-GAAP net income (loss) attributable to common shareholders of Sinovac for computing non-GAAP diluted earnings per share | |
| (16,088 | ) | |
| (36,431 | ) |
| | |
| | | |
| | |
| Weighted average number of shares on a diluted basis | |
| 99,638,043 | | |
| 114,227,276 | |
| Diluted earnings (loss) per share | |
| (0.08 | ) | |
| 0.15 | |
| Add: Non-GAAP adjustments to net income per share | |
| (0.08 | ) | |
| (0.47 | ) |
| Non-GAAP diluted loss per share | |
| (0.16 | ) | |
| (0.32 | ) |
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Dec 2024 to Jan 2025
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Jan 2024 to Jan 2025
